The costs of developing recombinant hemoglobin are giving at least some investors and companies pause.
DNX Corp. last week said it is dropping its program for developing a blood substitute from transgenic pigs, after having announced earlier that it wouldn't continue the program without a partner. "We set up some guidelines for ourselves very early on and we set a deadline that if we didn't have a partner on board we'd curtail the program," said Paul Schmitt, president and CEO.
Potential partners knew that modifying an existing plant for commercial production of DNXX's blood product would cost about $80 million, Schmitt